TRIM24 Degrading Bifunctional Compounds via E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies lack effective alternatives for inhibiting transcriptional intermediary factors like TRIM24, which are implicated in various cancers, with existing ligands showing underwhelming biological activity.
Innovation Solution
Development of novel bifunctional compounds that target TRIM24 by binding to both the protein and an E3 ubiquitin ligase, facilitating ubiquitination and proteasomal degradation, thereby modulating its levels in cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bifunctional compounds are designed to bind both TRIM24 and E3 ubiquitin ligase, then degradation efficacy is improved, but molecular complexity increases
Solution Approach 1:
The bifunctional compound is divided into two distinct functional modules: a TRIM24-binding moiety and an E3 ubiquitin ligase-binding moiety, connected by a linker. This segmentation allows each module to independently perform its specific binding function while working together to achieve protein degradation, resolving the contradiction between efficacy and complexity by making the complex molecule modular and manageable.
Solution Approach 2:
The patent merges two separate binding functions (TRIM24 binding and E3 ligase binding) into a single bifunctional molecule. By combining these two moieties with a linker, the compound can simultaneously engage both targets to induce ubiquitination and degradation of TRIM24, achieving high degradation efficacy while maintaining a unified molecular structure.
2Reliability
If novel bifunctional compounds are developed to target TRIM24, then therapeutic efficacy is improved, but development time and resources increase
Solution Approach 1:
The patent performs preliminary actions by designing and synthesizing a series of bifunctional compound candidates with different moieties and linkers before in vivo testing. This preliminary optimization of the molecular structure and binding properties accelerates the development process by identifying promising candidates early, reducing the overall development time while maintaining high therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively reduce TRIM24 levels, offering a promising therapeutic approach for cancers and other diseases mediated by TRIM24, with improved efficacy and safety profiles compared to existing inhibitors.
Implementation Method 1
The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases
Implementation Method 2
Bifunctional compounds composed of a target protein-binding moiety and an E3 ubiquitin ligase-binding moiety have been shown to induce proteasome-mediated degradation of selected proteins
Data Source
AI summary
The present application provides bifunctional compounds of Formula Ia or Ib:or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for tripartite motif-containing 24 (TRIM24). The present application also relates to methods for the targeted degradation of TRIM24 through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to TRIM24 which can be utilized in the treatment of disorders modulated by TRIM24.